ABSTRACT
Cervical cancer screening methodology has evolved and benefited from both new strategies and technologies. Detection of high-risk human papillomavirus (hrHPV) with molecular diagnostics continues to play a fundamental role in cervical cancer prevention, 1 and the validation of human papillomavirus (HPV) assays is essential to ensuring accurate identification of clinically relevant infection.
2, 3 The adoption of SurePath Preservative Fluid (SurePath; Becton Dickinson, Franklin Lakes, NJ) as a collection medium for cervical cytology presented challenges for DNA and RNA molecular diagnostics since this testing is often performed on the same sample collected for cytology. As early as the 1950s, publications demonstrated the difficulty of detecting nucleic acids in the presence of formaldehyde (formalin), one of the components of SurePath. 4 Later studies reported issues with SurePath fixation and nucleic acid recovery, 5, 6 and additional investigations confirmed that cross-linking between nucleic acids and proteins in the presence of formaldehyde rendered the DNA or RNA inaccessible to detection methods. 7 Without a preanalytic procedure that reverses the cross-linking and releases the DNA/RNA, hrHPV testing in SurePath could produce false-negative results. 8 In 2016, the US Food and Drug Administration (FDA) approved such a pretreatment procedure for use with the cobas HPV Test (Roche Molecular Systems, Pleasanton, CA) on specimens collected in SurePath medium, and a detailed description of the process has been published. 9 Assessment of HPV status to triage women with atypical squamous cells of undetermined significance (ASC-US) cytology results to colposcopy was the first intended use of HPV testing in cervical cancer screening 10 and remains the most common way in which HPV is used © American Society for Clinical Pathology AJCP / Original article in screening strategies. We describe here the performance of the cobas HPV test for the triage of ASC-US cytology results for samples collected in SurePath that have undergone pretreatment to reverse any SurePath-induced cross-linkage. Because a high percentage of women enrolled in this study had received the HPV vaccine, we also present preliminary data from a post hoc analysis evaluating the performance of HPV testing in a significantly vaccinated population.
Materials and Methods

Study Population and Protocol
Potential participants for the study were identified from a pool of women 21 years or older presenting for routine cervical cancer screening at Kaiser Permanente Southern California (KPSC), a large integrated managed care consortium. Per the KPSC standard of care, all women had two cervical samples taken at presentation, the first placed in SurePath for liquid-based cytology testing and the second in specimen transport medium (STM) for Hybrid Capture 2 DNA HPV testing (hc2; Qiagen, Gaithersburg, MD). As part of the study protocol, the cobas HPV test was also performed on the SurePath specimen, as described below. All women identified as having ASC-US cytology results were contacted by study coordinators and invited to participate in this study. Coordinators, participants, and health care providers were blinded to all HPV results during the enrollment process. Study inclusion criteria were as follows: 21 years or older, intact uterus, willing and able to undergo colposcopy within 12 weeks. Exclusion criteria included pregnancy, treatment for cervical intraepithelial neoplasia (CIN) within the previous 12 months, and current or planned participation in a clinical trial for HPV treatment. Those agreeing to participate returned within 12 weeks of the initial visit for a second colposcopy clinic visit at which informed consent and both a demographic and medical history were obtained.
The study protocol was approved by institutional review boards of all study sites, and written informed consent was obtained as prescribed.
Colposcopy
A colposcopy was performed per protocol on all participants after nonpregnancy status was verified, briefly as follows. All visible cervical lesions were biopsied, or in women with a satisfactory colposcopy but with no visible lesions, a random biopsy was taken at the squamocolumnar junction. An endocervical curettage (ECC) was performed in all women with an unsatisfactory colposcopy. Participants and colposcopists remained blinded to HPV status until colposcopy was completed. Biopsy and ECC specimens were read by consensus of an expert panel of KPSC pathologists (ie, central pathology review [CPR] ) who were masked to patient information and screening results; standard CIN terminology was used.
11
HPV Testing
The cobas HPV test simultaneously detects 14 hrHPV types by providing results for a pool of 12 hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , and 68, referred to as "12 other hrHPV" types), while also reporting individual results for HPV 16 and HPV 18, as well as for an internal β-globin control. 12 Testing with the cobas HPV test in SurePath was performed as described previously. 9 Briefly, all specimens were subjected to the preanalytic treatment in which an aliquot of the sample cell suspension from the SurePath vial was diluted 1:1 in a nucleophilic buffer, heated to 120°C for 20 minutes, cooled, vortexed, and then placed on the cobas 4800 system. cobas HPV testing was performed at three study laboratories: Southern California Permanente Regional Reference Laboratories, North Hollywood; Kaiser Permanente Northern California Regional Laboratory, Berkeley; and Roche Molecular Systems, Pleasanton, California. hc2 testing was performed at Southern California Permanente Regional Reference Laboratories on the sample collected in STM according to the manufacturer's instructions.
Statistical Analysis
Performance characteristics of the cobas HPV Test (sensitivity, specificity, positive predictive value [PPV] , and negative predictive value [NPV]) for identification of CIN grade 2 or worse (CIN2+) and CIN grade 3 or worse (CIN3+) were determined using standard statistical tests. A multinomial logistic regression was also performed to examine the effect of age, biopsy type, and vaccination status on the sensitivity of the cobas HPV test.
Results
Demographic and Medical History
A total of 958 women were enrolled and 952 (99.4%) were eligible to participate in the study. For cobas HPV testing, 865 (90.9%) specimens were available in SurePath and 943 (99.0%) for hc2 in STM; there were no invalid
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Tewari et al / cobas HPV TesT for asc-Us Triage in sUrePaTH results for either assay. Among eligible women, 99.0% (944/952) had colposcopy performed with 932 evaluable CPR biopsy results (11 were inadequate for diagnosis and one case was invalid due to unblinding of the pathologist). Of the 865 women with valid cobas HPV test results, 856 had CPR diagnosis available, including 10 inadequate for CPR read ❚Figure 1❚. Of the 943 women with valid hc2 results, 942 had CPR diagnosis available, including 11 inadequate for CPR read ( Figure 1 ).
The mean ± SD age of evaluable subjects was 35.4 ± 11.5 years; 41.4% were aged 21 to 29 years, and 16.8% were postmenopausal (Supplemental Table 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). Approximately 86% (733/856) of the total population and 88% (646/733) of women 25 years or older had Papanicolaou screening within the 5 years prior to enrollment. Of note, 31.8% of evaluable participants had received at least one dose of the HPV vaccine (Gardasil; Merck, Whitehouse Station, NJ), and of these, 71% had completed all three doses. Among evaluable women, 1.3% were reported as immunocompromised (Supplemental Table 1 ).
hrHPV and Disease Prevalence
The prevalence of hrHPV in the overall evaluable population for pooled 14 hrHPV, HPV 16, and HPV 18 was 45.8%, 6.5%, and 2.5%, respectively ❚Table 1❚. The expected highest prevalence was not observed in the youngest vaccine-eligible age group (21-29 years), and this was particularly notable for HPV 16 and HPV 18. However, a general decrease in HPV prevalence with age was seen in the older groups; a similar trend was observed with the hc2 test.
Among the ASC-US population with valid and adequate CPR results, biopsy-confirmed CIN grade 1 (CIN1) and CIN2 were diagnosed in 11.5% (97/846) and 5.1% (43/846) of women, respectively ❚Table 2❚. The prevalence of CIN2+ and CIN3+ was 8.9% (75/846) and 3.8% (32/846), respectively. HPV 16 and/or HPV 18 accounted for 8.2%, 14.0%, and 56.3% of CIN1, CIN2, and CIN3+, respectively (Table 2) . Of the 75 cases of CIN2+, 48 (64.0%) were detected with the directed biopsy, 23 (30.7%) with a random biopsy, and 4 (5.3%) with ECC; for study analyses, ECC was considered a random biopsy.
Performance of the cobas HPV Test
Sensitivity of the cobas HPV test for the detection of CIN2+ and CIN3+ in SurePath samples was 82.7% (95% confidence interval [CI], 72.6%-89.6%) and 87.5% (95% CI, 71.9%-95.2%), respectively ❚Table 3❚. Specificity was determined to be 57.5% (95% CI, 53.9%-60.9%) and 55.5% (95% CI, 52.1%-58.9%) for detecting CIN2+ and CIN3+, respectively ( Table 3 ). The remaining performance parameters for hc2 also yielded very similar values compared with cobas HPV (Table 3) .
Because the sensitivities of both cobas HPV in SurePath and hc2 in STM were observed to be slightly lower than what had been reported in similar studies, 13, 14 a post hoc analysis of the performance of the cobas HPV test for both the nonvaccinated and vaccinated cohorts was conducted in this highly vaccinated population. Sensitivity for the detection of CIN2+ and CIN3+ in the nonvaccinated population was 85% (95% CI, 70.9%-92.9%) and 89.5% (95% CI, 68.6%-97.1%), respectively, compared with 80.0% (95% CI, 64.1%-90.0%) and 84.6% (95% CI, 57.8%-95.7%) in the vaccinated population ❚Table 4❚. As with the overall population, all performance parameters for cobas HPV in SurePath were comparable to those determined for hc2 in STM for both the nonvaccinated and vaccinated populations ( Table 4) . A clear trend (not statistically significant) toward increased sensitivity in the nonvaccinated vs vaccinated populations was observed for both assays (Table 4) .
It is also notable that, similar to what has been reported in a previous study, 14 a difference in HPV sensitivity was evident between the directed and random biopsies overall and within the same vaccine status population (Table 4) ; although not achieving statistical significance, a consistent increase in sensitivity was observed using the directed vs the random biopsy independent of vaccine status. The sensitivity of cobas HPV for detection of CIN2+ when using the directed vs random biopsy to identify disease in the nonvaccinated population was 88.9% (95% CI, 71.9%-96.1%) compared with 76.9% (95% CI, 49.7%-91.8%); for CIN3+, sensitivity was determined to be 92.3% (95% CI, 66.7%-98.6%) compared with 83.3% (95% CI, 43.7%-97.0%) using the random biopsy (Table 4) . A similar trend of higher sensitivity of the directed biopsy vs the random biopsy was observed in the vaccinated population ( Table 4 ). The prevalence of cobas hrHPV was observed to be higher in the directed vs random biopsies independent of vaccine status, and this trend not unexpectedly correlated with sensitivity ❚Figure 2❚. Logistic regression analysis was also performed using the cobas test result (positive or negative) among disease cases as a dependent variable and with covariates as age, vaccination status, and biopsy type. Results (data not shown) indicated no effect by age or vaccination status (P > .05); however, biopsy type was significantly associated with sensitivity (P = .0421).
Discussion
This study was conducted to determine the performance of the cobas HPV test as an adjunct to ASC-US cytology for cervical specimens collected in SurePath. It Participants were enrolled from the population at a large integrated health care consortium that was unique in that it included a high percentage of women who had received the HPV vaccine (31.8%). Women with a cytology result of ASC-US, independent of HPV status, proceeded to colposcopy; colposcopy was performed per protocol that required directed biopsy of all visible lesions and a random biopsy at the squamocolumnar junction in the absence of visible lesions.
Comparison of the performance parameters of the cobas HPV test for samples collected in SurePath to the hc2 HPV test for samples collected in STM indicated comparable sensitivity, specificity, PPV, and NPV. This direct comparison of sensitivity and specificity also confirmed that the published criteria for validation of HPV test performance had been met. 2 Per the Meijer et al 2 criteria, the cobas HPV test achieved a sensitivity for the detection of CIN2+ of 90% of the sensitivity of hc2 and a specificity of at least 98% of that observed for hc2. Additional validation criteria were met by the cobas HPV test in SurePath specimens by achieving a mean target sensitivity of 92% ± 3% for detection of CIN3+, as proposed by Stoler et al. 3 The initial evaluation of the performance of the cobas HPV test in SurePath for the overall ASC-US population had a lower sensitivity for detection of CIN2+ and CIN3+ compared with results from the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study, which was conducted on PreservCyt (Hologic, Marlborough, MA) specimens. 13 However, a more focused analysis indicated that the lower sensitivity was not a function of testing in SurePath. First, the direct comparison to hc2 results
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❚Figure 2❚ Sensitivity for detection of high-grade CIN, prevalence of hrHPV, and prevalence of HPV 16/18 as a function of vaccination status and biopsy type for CIN2+ (A) and CIN3+ (B). CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus.
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Tewari et al / cobas HPV TesT for asc-Us Triage in sUrePaTH in specimens collected in STM indicated that all performance parameters for the cobas HPV test in SurePath were similar to hc2. Furthermore, the data suggested that sensitivity decreased when disease detected with the random biopsy was included, particularly in the vaccinated population where the rate of hrHPV positivity was lower. When analysis was confined to the nonvaccinated population and restricted to only disease identified by directed biopsy, we observed good agreement with what has been published in previous studies. 13, 14 The ATHENA study represented an essentially nonvaccinated population (4.3% of the ASC-US population enrolled had received the HPV vaccine) and reported a sensitivity of the cobas HPV test for ASC-US triage in samples collected in PreservCyt medium of 90% and 93.5% for CIN2+ and CIN3+, respectively. 13 When analysis in the current study is confined to the nonvaccinated population using the directed biopsies, sensitivities are comparable to what was observed in ATHENA, 13 thereby offering additional validation of the performance of cobas HPV in SurePath specimens that have undergone preanalytic treatment. Our performance data also agree with the results in the ASC-US population of the Clinical Evaluation of APTIMA mRNA (CLEAR) trial, 14 where HPV testing was performed with the Aptima HPV assay (Hologic) on samples collected in PreservCyt in a non-HPV-vaccinated population. A sensitivity for all biopsies of 86.8% (95% CI, 78.4%-92.3%) and 90.2% (95% CI, 77.5%-96.1%) for CIN2+ and CIN3+, respectively, was observed.
14 Similar to the study reported here, the sensitivities in the CLEAR trial for CIN2+ and CIN3+ also increased when the analysis was confined to the directed biopsy: 93.3% (95% CI, 84.1%-97.4%) and 93.1% (95% CI, 78.0%-98.1%), respectively. 14 The discordant sensitivities observed between the directed and random biopsies in both the CLEAR trial and the current study raise the questions of whether random biopsies detect clinically relevant disease 15 or whether performing only directed biopsies results in missing true positives and therefore overestimates the sensitivity. 14 The observation that the rate of hrHPV positivity was 2-fold lower in cases of high-grade disease detected with a random biopsy when no lesion was visible suggests that some of these HPV-negative cases may not represent significant disease.
The post hoc analysis of the performance of HPV in triaging ASC-US cytology in a significantly vaccinated population reported here is not intended to distract from our main objective of providing validation of the performance of HPV testing in SurePath. In the absence of a validated and FDA-approved HPV assay, concerns over the safety of HPV testing of specimens collected in SurePath have encouraged abandoning the use of SurePath cytology or the adoption of laboratory-developed tests to address issues of nucleic acid accessibility. The data presented here, by providing clinical validation of an HPV assay for samples collected in SurePath that have undergone preanalytic processing, mitigate concerns that false-negative results will occur in SurePath and eliminate the need for laboratory-developed tests or dual collection of specimens for cytology and HPV testing.
This study has several strengths. Women with ASC-US cytology results were enrolled from a large integrated health care system that provided a diverse US screening population. This is also the first prospective trial to evaluate and validate the performance of an HPV test in samples collected in SurePath that were subjected to a preanalytic procedure to reverse formaldehyde-induced cross-linking. Notably, this study also begins to address the important question for the medical community of whether HPV testing will remain effective with the continued uptake of prophylactic HPV vaccines. The data provided here support the performance of HPV testing for at least a limited population of HPV-vaccinated women. However, we caution that while vaccination rates of this study (~32%) mirrored current vaccination rates in the United States, 16 this study was not designed to evaluate this question and, indeed, invites additional questions. For example, the higher prevalence of CIN2+ and CIN3+ in the vaccinated vs the nonvaccinated population is counterintuitive, again raising speculation that some disease, particularly that detected by the random biopsy, may be a result of false-positive histology. A limitation of the study is the lack of specific vaccination history for the vaccinated cohort, and an alternative explanation for the higher disease prevalence in these women may be that some were immunized as a reaction to testing HPV positive. Moreover, the separate analyses of both the nonvaccinated and vaccinated populations and the directed and random biopsies resulted in low numbers in some populations, and this may be seen as an additional limitation of the current study. Future studies evaluating HPV testing should consider performance among vaccinated populations as a primary objective.
In summary, we have presented data to validate the performance of the cobas HPV test in samples collected in SurePath, a medium that is commonly used for combined cervical cytology assessment and nucleic acid detection. The preanalytic procedure performed on SurePath samples that is intended to reverse any cross-linkage prior to HPV testing maximizes accuracy and decreases the possibility of false-negative results. Cross-sectional performance to triage ASC-US cytology in the pretreated samples is comparable to what © American Society for Clinical Pathology AJCP / Original article was observed with the hc2 test on samples collected in STM, and a review of the literature also indicates good agreement with HPV results in the ASC-US population from other studies and with other HPV tests. In addition, the data offer important foresight into the future of HPV testing in the vaccinated era and warrant further investigation. 
